Menu
Search
|

Menu

Close
X

Odonate Therapeutics Inc ODT.OQ (NASDAQ Stock Exchange Global Select Market)

24.98 USD
+0.16 (+0.64%)
As of Jun 22
chart
Previous Close 24.82
Open 25.06
Volume 77,049
3m Avg Volume 26,142
Today’s High 25.11
Today’s Low 23.19
52 Week High 31.75
52 Week Low 15.15
Shares Outstanding (mil) 26.89
Market Capitalization (mil) 671.66
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.693
FY17
-1.194
FY16
-0.116
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.14
Price to Sales (TTM)
vs sector
--
8.17
Price to Book (MRQ)
vs sector
3.53
4.30
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.55
LT Debt to Equity (MRQ)
vs sector
0.00
13.12
Return on Investment (TTM)
vs sector
--
13.10
Return on Equity (TTM)
vs sector
--
15.09

EXECUTIVE LEADERSHIP

Kevin Tang
Chairman of the Board, Chief Executive Officer, Since 2013
Salary: $1.00
Bonus: --
Jeff Vacirca
Vice Chairman of the Board, Since 2016
Salary: --
Bonus: --
John Lemkey
Chief Financial Officer, Since 2013
Salary: --
Bonus: --
Robert Millham
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Stewart Kroll
Senior Vice President - Biometrics, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

4747 Executive Dr Ste 510
SAN DIEGO   CA   92121-3100

Phone: +1858.2003830

Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).

SPONSORED STORIES